Kiwi cannabis to ease German pain
Cannabis grown in the Ruato¯ria and East Coast communities is about to be legitimately sold to Germany for patients suffering pain.
Bioscience Limited has received its first order via its German distributor Nimbus Health, marking a significant commercial milestone for the exportfocused company.
Managing director Anna Stove says, “Receiving this order for dried flower from Nimbus signifies just how close we are to cementing export revenues and providing German patients with a sustainable supply of Rua medicines.”
The order is for Rua’s high THC flower, which has been developed through an extensive R&D programme by Cann Group, Rua’s Australian manufacturing, supply and technical services partner.
In Germany, medicinal driedcannabis flower is prescribed mainly for pain patients (70 per cent), and cannabis flowers with a THC content of greater than 20 per cent make up 77 per cent of cannabis flower prescriptions.
“At its launch, we believe Rua’s flower will be one of the highest THC dried flower medicines on the market, which will give Rua a significant competitive advantage,” she says.
While Rua looks to global markets, the company remains committed to its connection to Te Taira¯whiti and to patients across New Zealand having launched its first product in Aotearoa in April.
“The kaupapa to give back to the community will always be in our DNA and entering global markets will secure meaningful revenue so we can continue prioritising sustainable economic development in the Ruato¯ ria and East Coast communities,” Stove says. ■